– ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –
– ARCALYST 2026 expected net product revenue increased to $930 - $945 million –
– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end –
– Q1 2026 cash balance increased to $468.1 million –
– Conference call and webcast scheduled for 8:30 am ET today –
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Alibaba%20by%20Photo%20Agency%20via%20Shutterstock.jpg)
/An%20Intel%20sign%20out%20front%20of%20a%20corporate%20office%20by%20wolterke%20via%20Adobe%20Stock.jpeg)